FULCRUM THERAPEUTICS, INC.

FULC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $197.5M $58.2M $25.6M $35.1M $35.4M $57.1M $96.7M $72.8M
Accounts Receivable
Inventory
Total Current Assets $357.5M $249.9M $242.2M $207.5M $226.0M $119.5M $100.1M $74.1M
Property, Plant & Equipment $2.8M $3.9M $5.2M $6.9M $7.4M $8.4M $9.2M $10.5M
Goodwill
Intangible Assets (Excl. Goodwill)
Total Assets $366.3M $260.7M $257.7M $226.7M $235.0M $129.6M $110.4M $85.8M
Liabilities
Accounts Payable $1.6M $1.2M $2.8M $3.6M $4.8M $4.1M $2.2M $1.3M
Total Current Liabilities $13.0M $11.0M $13.7M $16.7M $19.2M $26.7M $12.1M $4.2M
Long-Term Debt
Total Liabilities $17.3M $17.7M $22.5M $27.7M $23.5M $34.4M $23.3M $9.8M
Stockholders' Equity
Retained Earnings $-594.3M $-519.4M $-509.7M $-412.3M $-302.5M $-221.6M $-150.8M $-68.1M
Total Stockholders' Equity $349.0M $243.0M $235.2M $198.9M $211.5M $95.2M $87.2M $-63.7M
← Newer Page 1 of 2 Older →